0001209191-21-034673.txt : 20210520 0001209191-21-034673.hdr.sgml : 20210520 20210520195600 ACCESSION NUMBER: 0001209191-21-034673 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210518 FILED AS OF DATE: 20210520 DATE AS OF CHANGE: 20210520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GADICKE ANSBERT CENTRAL INDEX KEY: 0001134655 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 21946231 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 54TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-18 0 0001808158 Repare Therapeutics Inc. RPTX 0001134655 GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Shares 2021-05-18 4 S 0 14773 33.90 D 4658065 I See Footnote Common Shares 2021-05-18 4 S 0 8541 34.61 D 4649524 I See Footnote Common Shares 2021-05-18 4 S 0 90 35.14 D 4649434 I See Footnote Common Shares 2021-05-18 4 J 0 21834 0.00 D 4627600 I See Footnote Common Shares 2021-05-19 4 S 0 9143 34.23 D 4618457 I See Footnote Common Shares 2021-05-19 4 S 0 4400 35.00 D 4614057 I See Footnote Common Shares 2021-05-20 4 S 0 9357 34.66 D 4604700 I See Footnote Common Shares 2021-05-20 4 S 0 600 35.19 D 4604100 I See Footnote Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. The shares were sold as follows: 6,292 by MPM BioVentures 2014, L.P. ("BV 2014"), 217 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,264 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.06 to $34.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,357,748 by BV 2014, 157,677 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 81,155 by AM BV2014 and 2,061,485 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 3,638 by BV 2014, 125 by AM BV2014 and 4,778 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.07 to $35.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,354,110 by BV 2014, 157,677 by BV 2014(B), 81,030 by AM BV2014 and 2,056,707 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 39 by BV 2014, 1 by AM BV2014 and 50 by UBS Oncology. The shares are held as follows: 2,354,071 by BV 2014, 157,677 by BV 2014(B), 81,029 by AM BV2014 and 2,056,657 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Represents a pro rata in-kind distribution from BV 2014(B) to its limited partners for no consideration. The shares are held as follows: 2,354,071 by BV 2014, 135,843 by BV 2014(B), 81,029 by AM BV2014 and 2,056,657 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 3,895 by BV 2014, 134 by AM BV2014 and 5,114 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.70 to $34.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,350,176 by BV 2014, 135,843 by BV 2014(B), 80,895 by AM BV2014 and 2,051,543 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 1,874 by BV 2014, 65 by AM BV2014 and 2,461 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.74 to $35.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,348,302 by BV 2014, 135,843 by BV 2014(B), 80,830 by AM BV2014 and 2,049,082 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 3,985 by BV 2014, 137 by AM BV2014 and 5,235 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.10 to $35.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,344,317 by BV 2014, 135,843 by BV 2014(B), 80,693 by AM BV2014 and 2,043,847 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 256 by BV 2014, 9 by AM BV2014 and 335 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.14 to $35.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,344,061 by BV 2014, 135,843 by BV 2014(B), 80,684 by AM BV2014 and 2,043,512 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. /s/ Ansbert Gadicke 2021-05-20